vs. Non- Candidemia in Critically Ill Patients: Clinical Outcomes, Risk Factors, and Mortality.

(now ) is an emerging pathogen that causes nosocomial candidemia, particularly in intensive care unit (ICU) settings. Its high resistance rates, prolonged environmental persistence, and outbreak potential underscore the need for robust comparative studies with non- species (NACS). In this retrospective, case-control study, adult ICU patients with candidemia were enrolled between April 2022 and October 2024. Clinical data, risk factors, and mortality at 14, 30, and 90 days were compared between the and NACS groups. Univariate and multivariate logistic regression analyses were performed to identify mortality-associated factors. Of the 182 patients analyzed, candidemia due to was identified in 33 (18.1%) cases, while 149 (81.9%) cases involved NACS. Fluconazole resistance ( < 0.001), prior antifungal exposure ( = 0.003), urinary catheter use ( = 0.040), and the length of ICU stay before the onset of candidemia ( < 0.001) were significantly higher in the cases. However, mortality rates at 14, 30, and 90 days were similar between the groups ( = 0.331, 0.108, and 0.273, respectively). The Sequential Organ Failure Assessment score was the only consistent independent predictor of mortality at all time points. In the NACS cases, the Pitt Bacteremia Score and sepsis also predicted 30- and 90-day mortality. While late recurrence was more frequent in the cases of , early recurrence and other risk factors were similar between the groups. candidemia was associated with higher fluconazole resistance, prior antifungal use, longer ICU stay, more frequent urinary catheterization, and later recurrence than the NACS cases. However, the mortality rates at 14, 30, and 90 days were comparable. Outcomes were primarily influenced by illness severity rather than the infecting species, highlighting the importance of timely therapy, stewardship, and infection control.